Primary Recommendation

Ergomed - Taking a share in a winning streak

October 2019

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

During the month I met with Ergomed’s finance director, Richard Barfield. I have met Barfield on a number of occasions during the past 20 years - first at public sector software business Northgate Information, later on at IT recruitment business Spring and finally at Arc International, a look-a-like business to chip supremo Arm, only much smaller. All three businesses were once quoted and ended up receiving takeover offers. After that, Barfield bid a friendly farewell to the PLC scene to join VC-backed Chiltern, a contract research organisation (CRO) that specialises in drug development services to pharmaceuticals and biotechs.Barfield points out that he was instrumental in establishing an acquisition strategy at Chiltern dur ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Market Comment - October '19

Filta - Watbio synergies revitalise UK side

Ergomed - Permira bids 1350p (September 2023)

Ergomed - 80%+ of this year’s forecast covered (September 2022)

Ergomed - Well set for an eps ‘beat’ (August 2022)

Ergomed (April 2022)

Ergomed - Buys specialist consultancy for £25.6m (March 2022)

Ergomed (October 2021)

Ergomed (May 2021)

Ergomed (January 2021)

Ergomed - "Hidden order bank" (October 2020)

Ergomed - Another big "beat" (August 2020)

Ergomed - Forecasts lifted again - by 5% (July 2020)

Ergomed - COVID-19 trial work underway (April 2020)

Ergomed - Earnings accretive deal (February 2020)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X